Interim report January - June 2008

Interim report January - June 2008

• Net sales in the second quarter amounted to 121.3 MSEK (131.1) and to 235.3
MSEK (250.0) in the period January - June 2008. At comparable exchange rates net
sales were unchanged in the second quarter and increased by 1 percent in the
first six months.

• The operating result for the second quarter amounted to 8.9 MSEK (11.1). The
operating result for the first six months 2008 amounted to 17.8 MSEK (18.3).

• The result after tax amounted to 8.0 MSEK (38.1) in the second quarter and to
21.2 MSEK (45.3) in the period January - June. In the second quarter 2007
capitalization of deferred income taxes recoverable was made to the amount of
27.6 MSEK.

• Earnings per share amounted to 0.09 SEK (0.43) in the second quarter and to
0.24 SEK (0.51) the first six months.

• The cash flow from operating activities amounted to 2.5 MSEK (-14.9) in the
second quarter and to 17.9 MSEK (-0.6) the first six months 2008.



Comments from CEO Torben Jörgensen
The strategic evaluation work has resulted in a numerous of projects and the
last phase of these projects has been begun. The evaluation is expected to be
finalized before the publishing of Biotages next interim report as per September
30, 2008. 

In the Biosystems business area sales continue to develop positively, with a 12
percent increase at comparable exchange rates. The launch of the new
PyroMark™Q24 instrument has been successful and we sold nine instruments in the
second quarter. We expect that the demand for and interest in the
Pyrosequencing® technology and its products continues to be high and sales
continue to grow strongly.

Discovery Chemistry is much affected by the restructuring within the major
pharma companies which resulted in a reduction of sales income with 3 percent at
comparable exchange rates.
The business area has carried out a number of successful introductions of new
products and new product launches. The launch of a new purification system,
Isolera, has been successful and sales accelerated towards the end of the
quarter. The new SNAP product area continues to develop favorable and has had
strongly growing sales. The sales of microwave equipment have had a changed
product mix and therefore lower sales income in Swedish currency. 

Direct sales in Europe have decreased in second quarter due to a weaker demand
from the largest Pharma industry companies. Sales in Asia continue to progress
well.

For further information, please contact:

Torben Jörgensen, President and CEO, phone: +46 707 49 05 84					
Mats-Olof Wallin, CFO, phone: +46 705 93 52 73

About Biotage
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market.
The company offers solutions, knowledge and experience in the areas of genetic
analysis and medicinal chemistry. In 2005 business and products from the company
Argonaut were acquired, further strengthening the product range in medicinal
chemistry. The customers include the world's top 30 pharma companies, the
world's top 20 biotech companies, and leading academic institutes. The company
is headquartered in Uppsala and has subsidiaries in the U.S., Japan, UK, Germany
and several other European countries. Biotage has 336 employees and had sales of
496 MSEK in 2007. Biotage is listed on the Stockholm stock exchange. Website:
www.biotage.com